AbbVie's lung cancer drug data disappoints; shares slump
(Reuters) - AbbVie Inc's experimental lung cancer drug data was not effective enough to seek a faster approval, in a setback to the company's efforts to build its cancer drug pipeline and cut dependence on its blockbuster Humira.
from Reuters: Health News http://reut.rs/2GgP2Uc
http://bit.ly/2zwRqiM